Mapping the Future: Identifying High-value Therapy Area Strategy for Emerging Markets

Background:

In an evolving global disease landscape, identifying the right therapy areas or indication setting for investment is a strategic move that defines a company’s growth trajectory, especially in emerging markets where potential is enormous but super fragmented. Our biopharma client, a global player aiming to expand their footprint in Asia-Pacific and Latin America, needed a reliable way to make informed, data-based decisions on where to focus its R&D and commercial resources.

Thelansis partnered with the client, leveraging its disease-area gold-standard disease burden data and market intelligence to help them pinpoint high-growth therapy areas and align their R&D priorities with market needs.

The client faced three key challenges:

• Scattered data sources with inconsistent disease and market reporting across countries.
• Limited visibility into disease burden trends and treatment landscape in rapidly evolving markets.
• Lack of an integrated framework to correlate epidemiological burden with commercial opportunity.

They needed a scalable, tech-based solution that could bring together diverse datasets and offer real-time, data-driven insights.

Thelansis Solution:

Our proprietary, gold-standard multidimensional dataset of disease burden and market intelligence, powered by an AI analytics platform, integrates multidimensional disease burden data to produce a priority-based therapy area matrix. We implemented a structured approach combining epidemiological insights, market analytics, and competitive intelligence.

Key Features:

Data Integration

·       Integrate primary market research, unstructured, and structured data to synthesize real-world data on disease burden.

·       Aggregated and standardized disease prevalence, incidence, and market size data from the public domain for 12 emerging markets.

·       Leveraged AI algorithms to identify correlations between disease burden, therapy availability, and probable market potential.

Epidemiology Landscape Mapping

·       Mapped therapy areas based on patient population density, growth rate, and unmet medical need.

·       Generated real-time epidemiological dashboards for regional and therapy-specific analysis.

Market Opportunity Assessment

·       Integrated therapy level market size, future projections, and pricing data.

·       Benchmarked therapy areas against historical launch success, regulatory complexity, and access environment.

Competitive & Access Intelligence

·       Integrated competitive landscape and regulatory timelines for each therapy area.

·       Highlighted white spaces and high-potential therapy zones for early R&D investment.

AI-Driven Prioritization Model

·       Built a scoring model and ranked therapy areas by combining disease prevalence, market attractiveness, and development feasibility.

·       Delivered a ranked opportunity matrix for short, mid, and long-term R&D focus.

Outcome:

• Identified 5 high-growth therapy areas across oncology, metabolic disorders, and infectious diseases for near-term investment.
• Reallocated 30% of R&D resources toward data-validated, high-return markets.
• Enhanced decision-making speed through real-time access to visual dashboards and dynamic analytics.
• Strengthened strategic planning, with unified visibility across epidemiology, competition, and commercial metrics.

By adopting Thelansis’s AI-based cloud solution, our client transitioned from intuition-driven decision-making to an evidence-based R&D strategy. The project exemplified how integrated data ecosystems can uncover untapped therapy area opportunities, mitigate investment risks, and enable smarter R&D allocation in emerging markets.

Read more: Mapping the Future: Identifying High-value Therapy Area Strategy for Emerging Markets